Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans

被引：20

作者：

Vincent J. ^{[1
]}

Dogolo L. ^{[1
]}

Baris B.A. ^{[1
]}

Willavize S.A. ^{[1
]}

Teng R. ^{[1
]}

机构：

[1] Central Research Division, Pfizer Inc., Groton, CT 06340, Eastern Point Road

来源：

European Journal of Clinical Microbiology and Infectious Diseases | 1998年 / 17卷 / 6期

关键词：

Internal Medicine; Serum Concentration; Prior Knowledge; Dose Regimen; Multiple Dose;

D O I：

10.1007/BF01691577

中图分类号：

学科分类号：

摘要：

A simplified dosing algorithm for trovafloxacin was evaluated following a single-dose infusion of alatrofloxacin at trovafloxacin equivalent doses of 30, 100, 200, 300 and 400 mg (57 subjects), and multiple doses of 200, 300 and 400 mg (30 subjects). Maximum serum concentration and area under the concentration-time curve for trovafloxacin increased with dose. Trovafloxacin clearance (82-85 ml.h/kg) and volume of distribution (1.3-1.6 l/kg) were independent of dose. Infusion of alatrofloxacin at a trovafloxacin equivalent dose of 300 mg at 1, 2 or 3 mg/ml over 1 h did not alter the pharmacokinetics of trovafloxacin. A plot of the weight-adjusted dose of trovafloxacin in individual subjects against the maximum serum concentration following single and multiple dosing, indicated that the maximum serum concentration increased 1 μg/ml for each 1 mg/kg of trovafloxacin administered. Thus, a prior knowledge of the desired serum concentration will permit appropriate dosing without the use of complex nomograms in patients with normal hepatic function.

引用

页码：427 / 430

页数：3

共 14 条

[1]

Neu H.C., Chin N.-X., In vitro activity of the new fluoroquinolone CP-99,219, Antimicrobial Agents and Chemotherapy, 38, pp. 2615-2622, (1994)

[2]

Briggs-Gooding B., Jones R.N., In vitro antimicrobial activity of CP-99,219, a novel azabicyclonaphthyridone, Antimicrobial Agents and Chemotherapy, 37, pp. 349-353, (1993)

[3]

Klugman K.P., Wasas A.J., In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae, Journal of Antimicrobial Chemotherapy, 36, pp. 873-874, (1995)

[4]

Felmingham D., Robbins M.J., Ingley K., Mathias I., Bhogal H., Leakey A., Ridgway G.L., Gruneberg R.N., In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates, Journal of Antimicrobial Chemotherapy, 39, SUPPL. B, pp. 43-49, (1997)

[5]

Child J., Andrews J., Boswell F., Brenwald N., Wise R., The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: A comparison with fluoroquinolone agents, Journal of Antimicrobial Chemotherapy, 35, pp. 869-876, (1995)

[6]

Endtz H.P., Mouton J.W., Den Hollander J.G., Van Den Braak N., Verbrugh H.A., Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections, Antimicrobial Agents and Chemotherapy, 41, pp. 1146-1149, (1997)

[7]

Gootz T.D., Brighty K.E., Anderson M.R., Schmieder B.J., Haskell S.L., Sutcliffe J.A., Castaldi M.J., McGuirk P.R., In vitro activity of CP-99,219, a novel 7-(3-azabicyclo [3.1.0] hexyl)-naphthyridone antimicrobial, Diagnostic Microbiology and Infectious Disease, 19, pp. 235-243, (1994)

[8]

Teng R., Harris S.C., Nix D.E., Schentag J.J., Foulds G., Liston T.E., Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers, Journal of Antimicrobial Chemotherapy, 36, pp. 385-394, (1995)

[9]

Girard A.E., Girard D., Gootz T.D., Faiella J.A., Cimochowski C.R., In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis, Antimicrobial Agents and Chemotherapy, 39, pp. 2210-2216, (1995)

[10]

Vincent J., Venitz J., Teng R., Baris B.A., Willavize S.A., Polzer R.J., Friedmen H.L., Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin, Journal of Antimicrobial Chemotherapy, 39, SUPPL. B, pp. 75-80, (1997)

← 1 2 →